Sort by
Refine Your Search
-
Research Fellow in Medicinal Chemistry (Chemical Biology) Job No.: 680924 Location: Parkville campus Employment Type: Full-time Duration: 12 months fixed-term appointment Remuneration: $80,464
-
, and may utilise iterative algorithms, machine learning and high-performance computing. Through the Monash Centre for Electron Microscopy, opportunities exist to acquire large experimental datasets using
-
modelling, and the economics of mental health Support economic analysis of healthcare utilisation, outcomes and costs using national datasets Develop and apply algorithms for cost-effectiveness analysis
-
optimisation.” The successful candidate will be involved in developing new mathematical theory and designing and implementing optimisation algorithms relevant to quantum information. The Research Fellow will
-
The Faculty of Pharmacy and Pharmaceutical Sciences at Monash University is seeking a Research Fellow (Level A) to join our world-class Drug Discovery Biology team at the Monash Institute of Pharmaceutical
-
of Pharmacy and Pharmaceutical Sciences at Monash University is seeking a Research Fellow (Level A) to join our world-class Drug Discovery Biology team at the Monash Institute of Pharmaceutical Sciences (MIPS
-
skills, coupled with well-developed planning and organisational abilities to manage multiple priorities effectively. Exceptional written and verbal communication skills, strict adherence to confidentiality
-
, computational chemistry, computational biology, or a closely related discipline. Demonstrated experience in the design of machine learning architectures such as GNNs, VAEs, or diffusion models applied
-
new tools. Experience in iPSC cell culture and differentiation, organ-on-chip technology, biomaterials, muscle biology, and microscopy is essential. About Monash University At Monash , work feels
-
translational research across a range of neurological conditions including epilepsy, neurodegeneration, multiple sclerosis, and traumatic brain injury. The department benefits from direct access to early-phase